Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Addition of sitagliptin to insulin (± metformin) in type 2 diabetes with inadequate glycemic control
2006-005051-15Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin add-on with Placebo add-on (2 arms). Primary endpoint: HbA1c change. Started Nov 2006; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-005051-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005051-15.